Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva’s Ellis Is New BBA Chair

Teva Welcomes Decision Of British Biosimilars Association

Executive Summary

Teva UK’s director of secondary care, Andrew Ellis, who has been a member of the British Biosimilars Association’s steering group, has now been appointed as its new chair.

You may also be interested in...



Upsher-Smith Launches Three New Generics

Upsher-Smith has strengthened its US generics portfolio with three new launches that will compete in a combined market worth nearly $102.5m.

Amgen Sues Pfizer Over US Pegfilgrastim Biosimilar

Amgen has filed a US patent-infringement lawsuit against Pfizer’s Hospira over its biosimilar pegfilgrastim rival to Neulasta.

Sawai’s Recent US Launches Outperform Expectations

Sawai’s sales increased on the back of a good performance from recently-launched products in the first nine months of its financial year. However, given the competitive environment the Japanese company is continuing to stick to its full-year forecasts.

Topics

Related Companies

UsernamePublicRestriction

Register

GB149606

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel